Contexto sectorial
Roivant Sciences Ltd [ROIV]
Última actualización 24 Jun 2026 @ 16:00 (Exchange is closed)
Último: $34.01
5.59%
3.67
GaG Algo Score™
v1.0
Corto
3.67
Medio
5.74 (↑)
Largo
5.69 (↑)
COMPRAR
48.98%
rentabilidad 3.40%
VENDER
54.00%
rentabilidad -15.80%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 16.13% | 16.13% | 2.99% |
| Pérdida % | -12.84% | -12.84% | 0.00% |
| Duración | 20.0d | 21d | 6.6d |
| Pivots encontrados | 4 |
| Tramos ganancia/pérdida | 3 (2 Ganancia / 1 Pérdida) |
| Último pivot | Top @ $32.21 el 2026-06-23 |
| Cambio desde el último pivot | $0.00 (0.00%) |
Predicción del próximo pivot Último: $34.01
| Próximo tipo previsto | Bottom |
| Precio previsto (prom.) | $28.08 |
| Precio previsto (mediana) | $28.08 |
| Rango de precio previsto (~68%) | $28.08 - $28.08 |
| Cambio al objetivo promedio | $-5.93 (-17.45%) |
| Fecha prevista (prom.) | 2026-07-13 |
| Rango de fechas previsto (~68%) | 2026-07-06 - 2026-07-19 |
| Base | Based on 1 historical losses (Avg: -12.84%, Median: -12.84%, StdDev of Abs: 0.00%) and duration (Avg: 20.0 days, StdDev: 6.6 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Roivant Sciences Ltd climbs 3.07%.
Roivant Sciences Ltd (ROIV) stock price surged on Tuesday after the stock rose $0.960 (3.07%) from the previous session on above-average volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.43%. Yesterday's trading volume was 7.36M shares, worth about $237.23M. This represents 486 831 shares more than the day before. Volume was above the 10-day average of 5.45M shares.
Roivant Sciences Ltd signals
The last moves is moving the stock closer to overbought levels, which may signal growing momentum but also increasing risk of a pullback. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Strong Bullish Consensus: A powerful wave of positive momentum is evident across all timeframes. Technical indicators are decisively bullish in the short-term (19/30, net +50%), medium-term (19/30, net +50%), and long-term (19/30, net +50%), signaling a robust and sustained uptrend.
Roivant Sciences Ltd Support & Resistance Levels
The stock is approaching the closest resistance level at $32.40. approximately $0.190 (0.59%) away. Consolidating near resistance. Breaking above this level could signal further upside where next resistance level will be found at $. On a fall back there will be support at $11.6 The dis das resistance s111.6 -
Roivant Sciences Ltd Evaluation
- Corto puntuación: 3.67
- Medio puntuación: 5.74
- Largo puntuación: 5.69
Flujo de propiedad
GetAGraph InsiderPower
Transacciones
537
Fuerza compradora
1.40B
Fuerza vendedora
2.20B
Fiabilidad
100/100
Compra / venta
0.64
Corr. hist.
-0.70
Última señal
Buy 2026-06-23
Director 220
Executive 208
Officer 71
Major holder 37
2026-06-20
Pulik Richard Officer
Other 2 129
2026-06-20
Humes Jennifer Officer
Other 3 582
2026-05-22
Venker Eric Executive
Sell 200 000
2026-05-22
Venker Eric Executive
Buy 200 000
2026-05-20
Venker Eric Executive
Sell 34 483
2026-05-20
Pulik Richard Officer
Sell 18 962
Mapa de relación
Resumen de correlación
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.50% <strong>$34.19</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
5.21%
Of outstanding shares
Short float
7.46%
Of tradable float
Days to cover
4.14
Short interest divided by average volume
Squeeze probability
25.30%
+32.35% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
9
EPS beats
6
EPS misses
3
Avg. surprise
7.31%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q4/2025 | 2025-11-10 | - | - | - | - |
| Q3/2025 | 2025-08-06 | - | - | - | - |
| Q2/2025 | 2025-05-29 | - | $-0.160 | - | - |
| Q1/2025 | 2025-02-10 | $-0.130 | $-0.240 | 45.83% | 9.02M |
| Q4/2024 | 2024-11-12 | $-0.290 | $-0.247 | -17.41% | 4.48M |
| Q3/2024 | 2024-08-08 | $-0.180 | $-0.243 | 26.03% | 55.13M |
| Q2/2024 | 2024-05-30 | $-0.230 | $-0.264 | 12.99% | 28.93M |
| Q1/2024 | 2024-02-13 | $-0.210 | $-0.270 | 22.22% | 37.14M |
Analyst view
Analyst targets
Consensus
$37.17
Median
$38.00
Low
$30.00
High
$42.00
News flow
Latest company news
Market coverage
seekingalpha.com Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Jun 9, 2026 seekingalpha.com Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript Jun 3, 2026 seekingalpha.com Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript May 29, 2026 seekingalpha.com Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy May 21, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
Roivant Sciences Ltd is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs The firms development pipeline targets a broad spectrum of diseases including various forms of solid tumors and oncologic malignancies hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia as well as rare conditions such as hypophosphatasia Additionally Roivant is developing treatments for immunological and dermatological ailments including psoriasis atopic dermatitis vitiligo hyperhidrosis acne myasthenia gravis thyroid eye diseases and sarcoidosis alongside tackling infections like staph aureus bacteremia Founded in 2014 its operations are based in London United Kingdom
Navigation